To Compare the Ischemic Pre-Conditioning and Post-Conditioning on Reperfusion Injury in Humans.
Reperfusion Injury occurs by the sudden blood flow to the injured and ischemic myocardium during restoration of blood flow either by Mechanical revascularization or thrombolysis. A phenomenon known as Pre-conditioning has been identified to limit the the extent and severity of reperfusion injury but it is very difficult to apply it in patient care setting as timing of acute cardiac or neurologic ischemic event is difficult to reliably predict.
Postconditioning or ischemic postconditioning is well known to attenuate the reperfusion injury. There is enough data that shows the benefit of post conditioning in reducing the reperfusion injury in animals. However postconditioning in humans has not been investigated.
We hypothesize that Post conditioning will attenuate the reperfusion injury and will be comparable to the effect of preconditioning in humans.
Myocardial ischemia is one on the leading causes of mortality and morbidity in the United States. The initial injury to the myocardium is due to a state of imbalance when oxygen demand exceeds supply. This is most pronounced in the cases of sudden total occlusion of a coronary artery that results in myocardial injury and necrosis (AMI). The main stay of the therapy in these cases is the restoration of the flow to the ischemic myocardium by means of reperfusion therapy such as thrombolysis or mechanical revascularization. Interestingly, there is data to suggest that sudden restoration of blood flow to the ischemic myocardium may cause another form of myocardial injury ,known as reperfusion injury.
Although initially controversial, reperfusion injury is now recognized as a distinct entity. This refers to the sudden and brisk reperfusion of ischemic myocardium that may induce injury that was not originally present-paradoxically exaggerating the end result of an ischemic event. Reperfusion injury may increase infarct size, decrease myocardial contractile function and induce or exaggerate vascular endothelial dysfunction. The pathophysiology is not well understood, but some of the effects of reperfusion injury have been attributed to the generation of free oxygen radical and increased oxidative stress possibly related to the abnormalities of the nitric oxide synthase (NOS) enzyme and its byproducts. These cellular events lead to the endothelial dysfunction, a pivotal event in the development of reperfusion injury.
A concept known as pre-conditioning has been identified as a phenomenon that limits the extent and severity of reperfusion injury. Classically, preconditioning refers to the occurrence whereby repeated brief episodes of ischemia preceding a prolonged period of ischemia results in marked diminution of ischemic injury and injury occurring during reperfusion. The mechanism of this ischemic tolerance was thought to be secondary to the recruitment of collateral circulation, as it was noted to develop in patients undergoing serial balloon inflations during angioplasty. The cellular mechanism involved in ischemic preconditioning are not completely understood, but may be related to the attenuation of reperfusion injury. These findings are also corroborated by Kharbanda's group in their findings made after inducing forearm ischemia in 31 healthy volunteers. In an attempt to test the effects of ischemic preconditioning on the attenuation of ischemia-reperfusion injury as it pertains to endothelial function and circulating blood cell function, the forearms of these volunteers were made ischemic for a 20 minutes period using a pneumatic blood pressure cuff to 200 mmHg. This method was then compared to the use of ischemic preconditioning prior to the prolonged 20 minutes ischemic episode. Ischemic preconditioning was induced by inflating the pneumatic cuff to 200 mmhg for 5 minutes and then deflating the cuff. This was repeated for a total of 3 times. Radial artery reactivity testing and blood samples were collected from the antecubital vein at timed intervals after cuff deflation in both methods. It was noted that ischemic -preconditioning prior to prolonged forearm ischemia prevented both endothelial dysfunction and neutrophil activation.
Unfortunately, although pre-conditioning has been extensively studied and has shown to reduce reperfusion injury in both animal and human models, it is difficult to practically apply this in a patient-care setting. This is because the timing of acute cardiac or neurologic ischemic events is difficult to reliably predict. Accordingly, this has generated great interest in a theory known as post-conditioning. Post conditioning or ischemic post-conditioning is a concept whereby short, repetitive ischemic episodes applied during early reperfusion of ischemic myocardium will attenuate reperfusion injury. It appears that both pre-conditioning and post-conditioning target the same pathophysiological mechanism, or share effects on a final common pathway involved in the pathogenesis of reperfusion injury. In a recent study, the effects of ischemic post-conditioning were compared to ischemic preconditioning in the coronary circulation of an animal model. An open chest, left anterior descending coronary artery occlusion model was used in 29 dots (10 controls, 9 preconditioning, and 10 post-conditioning). When compared to controls, both interventions showed protective myocardial effects. The strategy of post-conditioning had comparable results to ischemic preconditioning regarding reduction in infarct size.
Endothelial dysfunction is on of the signs of early atherosclerosis, and also a major component of ischemia-reperfusion injury. Several factors affect endothelial function, but the presence of reactive oxygen species in the vessel wall and the ability of endothelium to generated nitric oxide (NO) seem to be the most important determinants of endothelial function. Due to abnormalities in NOS, the generation of free oxygen radicals increases, and the level of NO decreases during an ischemic episode. This leads to significant alterations in the endothelial function. Under ischemic conditions, nitric oxide synthase produces superoxide (.O2-) in excess of nitric oxide (NO). Superoxide can react with the surrounding nitric oxide to produce a potent oxidizing agent, peroxynitrite (ONOO-). These oxygen radicals are thought to contribute to the development of ischemia-reperfusion injury in humans. NO has been shown to play a significant role in reducing reperfusion injury in humans. The group from our institution demonstrated this where reperfusion injury in the forearm of human subjects was attenuated by the administration of tetrahydrobiopterin (BH4), a cofactor for NOS that leads to the production of NO (unpublished data, Baballiaros et al.). The time course for oxidative marker expression, such as NO, after ischemia-reperfusion injury is expected to occur as early as 2.5 to 5 minutes after reperfusion. Several studies have examined the time course of NO, nitrosyl hemoglobin, glutathione reduction-oxidation, and hydro peroxides. In a study conducted by Mochizuki et al, describing an arterial flow mediated dilation model, NO attained a peak value with a first-order time delay and the peak level NO concentration was linearly correlated with perfusion rate in each vessel. It must be noted, however, that the peak and duration of the levels are somewhat variable and depend on perfusion flow and the diameter of the vessel.
Endothelial function can be non-invasively evaluated using Brachial (or Radial) artery reactivity testing (BART) as a measure of flow-mediated dilation (FMD). Since it’s beginnings in 1989, the study of FMD has now taken on an expanded role in the understanding of endothelial physiology. FMD is an endothelial dependent process that reflects relaxation of a conduit artery when exposed to shear stress. Increased flow, and thereby increased shear stress, through the brachial artery occurs after post occlusive reactive hyperemia. Several studies have suggested that the maximal increase in diameter occurs after approximately 60 seconds after the release of the occlusive cuff or after 45-60 seconds after peak reactive hyperemia blood flow. The increase in diameter at this time is prevented by the NO synthase inhibitor, N-G monomethyl-L-arginine, indicating that it is an endothelial dependent process mediated by NO. Other measures of vasodilator response include time to maximum response, duration of the vasodilator response, and the area under the dilation curve .An impairment of endothelial function, via FMD assessment by BART, has been shown to correlate with risk factors for coronary artery disease (smoking, hyperlipidemia, diabetes mellitus) and adverse cardiovascular events.
Currently, there is data that shows the benefit of post-conditioning in reducing reperfusion injury in animal models only. However the use of post-conditioning in humans to reduce reperfusion injury has not been well investigated.Given that endothelial dysfunction is a significant component of reperfusion injury, we propose to examine the effects of post-conditioning on a reperfusion injury by using BART. This study will act as a pilot by which we can compare the results of Post-conditioning to preconditioning to reduce the reperfusion injury with BART in a human reperfusion injury model. The clinical relevance of this study is paramount. If it can be shown that post-conditioning attenuates reperfusion injury in humans, as assessed by BART a larger scale trial to assess post-conditioning on prevention of ischemia reperfusion injury in humans will be necessary. Furthermore, this allows for a possible therapeutic application in the clinical setting, such as potentially providing post-conditioning measures to patients undergoing percutaneous coronary intervention for abruptly occluded coronary arteries. Attenuation of reperfusion injury may further reduce the associated morbidity and mortality of acute coronary ischemic events.
Observational Model: Case Control, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective
Emory University Hospital
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00385151
- Information obtained from ClinicalTrials.gov on July 15, 2010
Peripheral and coronary endothelial dysfunction in type 2 diabetic patients may be influenced by therapeutics. Using Radial flow monitoring and myocardial perfusion magnetic resonance imag...
The overall hypotheses of this project is that severe sepsis is associated with endothelial dysfunction; that endothelial dysfunction, in turn, is predictive of subsequent organ failure an...
Our objective is to determine whether HIV infected youth have higher level of endothelial dysfunction, as measured by Peripheral Arterial Tonometry, when compared to age matched healthy co...
This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunc...
This is a randomized clinical trial, double-blind, placebo controlled, to verify if simvastatin can improve erectile dysfunction in men with endothelial dysfunction, without any cardiac di...
Although endothelial dysfunction is central to the pathogenesis of sepsis, no specific and clinically applicable marker for endothelial dysfunction is currently available. Endocan, a proteoglycan excr...
In this study, we examined the effects of Brucella infection on endothelial dysfunction. Flow-mediated dilatation (FMD) measurement is indicator of the endothelial function, and abnormal values indica...
Therapies to prevent or reverse endothelial dysfunction and vascular leak found in dengue hemorrhagic fever (DHF) have not been identified.In this review we summarize dengue viruses and the spectrum o...
Endothelial dysfunction plays a key role in the pathogenesis of cardiovascular disease. However, the gender-related differences in risk factors for endothelial dysfunction are controversial. We invest...
Placenta-derived circulating factors contribute to the maternal endothelial dysfunction underlying preeclampsia. Endothelial colony forming cells (ECFC), a sub-population of endothelial progenitor cel...
Medical and Biotech [MESH] Definitions
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR C in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.
A vascular endothelial growth factor that specifically binds to VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 and VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3. In addition to being an angiogenic factor it can act on LYMPHATIC VESSELS to stimulate LYMPHANGIOGENESIS. It is similar in structure to VASCULAR ENDOTHELIAL GROWTH FACTOR D in that they both contain N- and C-terminal extensions that were not found in other VEGF family members.
A vascular endothelial cell growth factor receptor whose expression is restricted primarily to adult lymphatic endothelium. VEGFR-3 preferentially binds the vascular endothelial growth factor C and vascular endothelial growth factor D and may be involved in the control of lymphangiogenesis.
A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.